Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Prototype HIV-1 vaccine data

The company reported on one individual enrolled in a 30-patient Phase I trial of its prototype vaccine, which

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE